274 related articles for article (PubMed ID: 9933821)
41. Biochemical screening of fetal aneuploidies and neural tube defects by "double-test" in Croatia: a 10 years' experience.
Tislarić-Medenjak D; Kosec V; Tonković-Durisević I; Zec I; Sabolović-Rudman S; Kuna K; Herman R; Ivicević-Bakulić T; Soljacić-Vranes H; Tuckar N; Muzinić D; Butorac D; Bolanca I; Kosec A; Stipoljev F
Coll Antropol; 2011 Sep; 35(3):957-62. PubMed ID: 22053587
[TBL] [Abstract][Full Text] [Related]
42. The effect of gestational age on the detection rate of Down's syndrome by maternal serum alpha-fetoprotein screening.
Greenberg F; Del Junco D; Weyland B; Faucett WA; Schmidt D; Rose E; Alpert E
Am J Obstet Gynecol; 1991 Nov; 165(5 Pt 1):1391-3. PubMed ID: 1720281
[TBL] [Abstract][Full Text] [Related]
43. [AFP, uE3, beta-hCG levels applied for prenatal diagnosis of Down's syndrome].
Liao S; Wang Y; Ye G
Zhonghua Fu Chan Ke Za Zhi; 1997 Nov; 32(11):655-8. PubMed ID: 9639764
[TBL] [Abstract][Full Text] [Related]
44. Effect of incorrect gestational dating on Down's syndrome and neural tube risk assessment.
Millner SN
Ann Clin Biochem; 2001 May; 38(Pt 3):230-4. PubMed ID: 11392497
[TBL] [Abstract][Full Text] [Related]
45. 'Dual positivity' for neural tube defects and down syndrome at maternal serum screening: gestational outcome.
Zanini R; Tarantini M; Cerri V; Jacobello C; Bellotti D; Lancetti S; Scalchi S; Groli C; Bianchi UA
Fetal Diagn Ther; 1998; 13(2):106-10. PubMed ID: 9650657
[TBL] [Abstract][Full Text] [Related]
46. Serum markers for Down's syndrome in relation to number of previous births and maternal age.
Wald NJ; Watt HC
Prenat Diagn; 1996 Aug; 16(8):699-703. PubMed ID: 8878278
[TBL] [Abstract][Full Text] [Related]
47. [The prenatal diagnosis of Down's syndrome based on the biochemical screening of maternal serum markers].
Arbuzova SB; Nikolenko MI; Khlevnaia LA; Fedotova OO; Solov'eva VD; Malova SA
Tsitol Genet; 1998; 32(1):66-71. PubMed ID: 9695254
[TBL] [Abstract][Full Text] [Related]
48. Urine free beta hCG and beta core in pregnancies affected by Down's syndrome.
Spencer K; Aitken DA; Macri JN; Buchanan PD
Prenat Diagn; 1996 Jul; 16(7):605-13. PubMed ID: 8843469
[TBL] [Abstract][Full Text] [Related]
49. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters.
Wald NJ; Watt HC; Hackshaw AK
N Engl J Med; 1999 Aug; 341(7):461-7. PubMed ID: 10441601
[TBL] [Abstract][Full Text] [Related]
50. [Evaluation of Down's syndrome screening methods using maternal serum biochemistry in the second trimester pregnancy].
Yu DY; Fu P; Zhang ZH; Wang F; Han MY; Ren HY; Zhao W; Zhang K; Li S; Jiang N
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Jun; 28(3):332-5. PubMed ID: 21644235
[TBL] [Abstract][Full Text] [Related]
51. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
Orlandi F; Damiani G; Hallahan TW; Krantz DA; Macri JN
Ultrasound Obstet Gynecol; 1997 Dec; 10(6):381-6. PubMed ID: 9476320
[TBL] [Abstract][Full Text] [Related]
52. Dual Analyte immunoassay--a new approach to neural tube defect and Down's syndrome screening.
Macri JN; Spencer K; Anderson R
Ann Clin Biochem; 1992 Jul; 29 ( Pt 4)():390-6. PubMed ID: 1379420
[TBL] [Abstract][Full Text] [Related]
53. Second trimester prenatal screening for Down's syndrome in Mainland Chinese subjects using double-marker analysis of α-fetoprotein and β-human chorionic gonadotropin combined with measurement of nuchal fold thickness.
Liu F; Liang H; Jiang X; Zhang Y; Xue L; Yang C; Cheng J; Liu P; Liu Y; Guo X
Ann Acad Med Singap; 2011 Jul; 40(7):315-8. PubMed ID: 21870022
[TBL] [Abstract][Full Text] [Related]
54. Prediction of adverse perinatal outcome by maternal serum screening for Down syndrome in an Asian population.
Hsieh TT; Hung TH; Hsu JJ; Shau WY; Su CW; Hsieh FJ
Obstet Gynecol; 1997 Jun; 89(6):937-40. PubMed ID: 9170469
[TBL] [Abstract][Full Text] [Related]
55. Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome.
Wald NJ; Cuckle HS; Densem JW; Nanchahal K; Canick JA; Haddow JE; Knight GJ; Palomaki GE
Br J Obstet Gynaecol; 1988 Apr; 95(4):334-41. PubMed ID: 2454652
[TBL] [Abstract][Full Text] [Related]
56. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
[TBL] [Abstract][Full Text] [Related]
57. First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free beta-hCG and pregnancy-associated plasma protein-A assays.
Spencer K
Ann Clin Biochem; 2005 Jan; 42(Pt 1):30-40. PubMed ID: 15802030
[TBL] [Abstract][Full Text] [Related]
58. [Screening for Down's syndrome: results at the Klimentská Polyclinic Screening Center 1992-1994].
Stejskal D; Hlavová E; Cerný M; Polívková Z; Bíbrová J
Ceska Gynekol; 1995 Feb; 60(1):17-21. PubMed ID: 7536599
[TBL] [Abstract][Full Text] [Related]
59. Efficiency of ultrasound and biochemical markers for Down's syndrome risk screening. A prospective study.
Benattar C; Audibert F; Taieb J; Ville Y; Roberto A; Lindenbaum A; Frydman R
Fetal Diagn Ther; 1999; 14(2):112-7. PubMed ID: 10085510
[TBL] [Abstract][Full Text] [Related]
60. Down's syndrome risk estimates demonstrate considerable heterogeneity despite homogeneity of input.
Reynolds T; Ellis A; Jones R
Ann Clin Biochem; 2004 Nov; 41(Pt 6):464-8. PubMed ID: 15588435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
